Spire Healthcare attracts credible PE interest and sparks valuation debate

Spire Healthcare confirmed preliminary talks with private equity bidders Bridgepoint and Triton, prompting a c.20% intraday share jump to 214p and renewed debate over the company’s valuation. Analysts at Panmure Liberum and Peel Hunt view the suitors as credible—Panmure flags 250p as a minimum acceptable bid and >300p as fair value—while Peel Hunt argues the £714m market cap materially undervalues the operating business and around £1.4bn of freehold real estate. Spire reported revenue growth of 3.6% since July and now expects FY25 adjusted group EBITDA at the bottom end of its £270–285m guidance range, with temporary NHS commissioning weakness cited as the near-term drag.

Analysis

Market structure: Spire (SPI.L) is a clear winner if a competitive auction emerges—market cap ~£714m vs quoted freeholds ~£1.4bn implies a material asset revaluation tailwind; Panmure’s 250–300p reference implies 40–70% upside from ~177p and a near-term takeover premium. PE buyers (Bridgepoint, Triton) gain accretive cashflow and real‑estate optionality; NHS and commissioners are neutral-to-loser if private capacity is priced higher. Cross-asset: a deal financed with GBP debt would modestly tighten UK high‑yield spreads and support regional REITs; sterling could strengthen 1–2% on sizeable GBP funding news.

Risk assessment: Tail risks include a failed auction, CMA/competition blockage, or a UK policy pivot to limit private provider use—each could erase >30–50% of potential upside. Immediate (days): price volatility around process updates; short-term (weeks–months): bid process and indicative offers; long-term (quarters): NHS commissioning normalisation affecting EBITDA margin recovery. Hidden dependency: valuations hinge on property yield compression and interest rates—high rates reduce NAV even if operations are stable. Key catalysts: management sale update (next 2–6 weeks), formal approach, or final bid — and any CMA filing.

Trade implications: Direct: establish a 2–3% NAV long position in SPI.L at current levels (≈177p) with a hard stop at 150p, initial target 250p (take 50% profit) and stretch target 300p within 6–12 months. Options: buy a modest Jun‑26 200p/320p call spread sized at 0.75–1% NAV to cap cost while keeping upside to ~300p. Sector: overweight UK healthcare estate plays (e.g., Primary Health Properties PHP.L size 1–2% NAV) and underweight broad UK small‑cap exposure if funding risk rises.

Contrarian angles: Consensus undervalues execution risk—PE buyers may cease if leverage or NHS demand uncertainty rises, so the 20% pop to 214p could be overdone absent competitive tension. Historical parallels (UK mid‑cap takeovers with property premiums) show bids often land 40–60% above pre‑rumour levels, but ~30% of processes fail or settle below initial advertiser targets. Unintended consequence: a leveraged buyout could hollow operational investment, harming medium‑term EBITDA and triggering covenant risk; price action post-offer could therefore be binary.

Key Decisions for Investors

• Initiate a 2–3% NAV long in SPI.L at current market (~170–180p). Set stop-loss at 150p, take 50% off at 250p and trim remaining at 300p; hold remainder for up to 12 months if process continues.
• Purchase Jun‑26 SPI.L 200p/320p call spread sized to 0.75–1% NAV to express takeover upside while limiting premium spend; reassess after any first‑round bids or management update within 2–6 weeks.
• Add a 1–2% NAV tactical long to Primary Health Properties (PHP.L) to play potential re‑rating of healthcare real‑estate if SPI trade accelerates; exit if UK yields rise >50bp from current level.
• Avoid/leverage‑light positions in UK healthcare operators with heavy NHS commissioning dependence until FY26 guidance clarity—reduce exposure by 20–30% within 30 days if no return to normal commissioning is signalled.
• Monitor catalysts daily: (1) Spire management announcements and advisor timetable (next 2–6 weeks), (2) any formal approaches filed with CMA (risk window 30–180 days), and (3) UK government statements on private provider usage; act to tighten stops or take profits on material developments.